Vancouver-based Kardium Inc. secures $340 million in funding for its atrial fibrillation treatment technology. The company aims for rapid commercial success with FDA approval and strong clinical results. Kardium’s innovative device uses pulsed field ablation to target problem cells in the heart. The company plans to expand manufacturing and hire more staff to meet growing demand.
Read more@
